Literature DB >> 21295176

Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease.

Craig S Broberg1, Ananda R Jayaweera, Gerhard P Diller, Sanjay K Prasad, Swee Lay Thein, Bridget E Bax, John Burman, Michael A Gatzoulis.   

Abstract

In patients with cyanosis from congenital heart disease, erythropoiesis is governed by many factors that can alter the expected relation between the oxygen saturation (O(2sat)) and hemoglobin concentration. We sought to define the relation between the O(2sat) and hemoglobin in such patients and to predict an ideal hemoglobin concentration for a given O(2sat). Adults with congenital heart defects and cyanosis were studied prospectively using blood tests and exercise testing. Nonoptimal hemoglobin was defined as any evidence of inadequate erythropoiesis (i.e., iron, folate, or vitamin B(12) deficiency, increased erythropoietin, reticulocytosis, or a right-shifted oxygen-hemoglobin curve). For patients without these factors, a linear regression equation of hemoglobin versus O(2sat) was used to predict the optimal hemoglobin for all patients. Of the 65 patients studied, 21 met all the prestudy criteria for an optimal hemoglobin. For all patients, no correlation was found between O(2sat) and hemoglobin (r = -0.22). However, a strong linear correlation was found for those meeting the criteria for optimal hemoglobin (r = -0.865, p <0.001). The optimal hemoglobin regression equation was as follows: predicted hemoglobin = 57.5 - (0.444 × O(2sat)). A negative correlation was found between the hemoglobin difference (predicted minus measured) and exercise duration on cardiopulmonary exercise testing (r = -0.396, p = 0.005) and the 6-minute walk distance (r = -0.468, p <0.001). In conclusion, a strong relation between O(2sat) and hemoglobin concentration can be shown in stable cyanotic patients and used to predict an optimal hemoglobin. This relation might be useful in defining functional anemia in this group.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295176     DOI: 10.1016/j.amjcard.2010.10.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Current Role of Blood and Urine Biomarkers in the Clinical Care of Adults with Congenital Heart Disease.

Authors:  Saurabh Rajpal; Laith Alshawabkeh; Alexander R Opotowsky
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

2.  Red Blood Cell Transfusion in the Postoperative Care of Pediatric Cardiac Surgery: Survey on Stated Practice.

Authors:  Jean-Sébastien Tremblay-Roy; Nancy Poirier; Thierry Ducruet; Jacques Lacroix; Karen Harrington
Journal:  Pediatr Cardiol       Date:  2016-07-05       Impact factor: 1.655

3.  Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome.

Authors:  Cristel S Hjortshøj; Thomas Gilljam; Göran Dellgren; Markku O Pentikäinen; Thomas Möller; Annette Schophuus Jensen; Maila Turanlahti; Ulf Thilén; Finn Gustafsson; Lars Søndergaard
Journal:  Heart       Date:  2019-08-21       Impact factor: 5.994

4.  Preoperative Hemoglobin Level, Oxygen Saturation and Postoperative Outcomes in Children With Cyanotic Congenital Heart Disease: A Propensity-Score Matching Analysis.

Authors:  Dan Zhou; Li-Jing Deng; Yun-Fei Ling; Meng-Lin Tang
Journal:  Front Pediatr       Date:  2022-01-21       Impact factor: 3.418

5.  Nocturnal hypoxaemia in patients with Eisenmenger syndrome: a cohort study.

Authors:  Sivasubramanian Ramakrishnan; Rajnish Juneja; Neil Bardolei; Ajay Sharma; Garima Shukla; Manvir Bhatia; Mani Kalaivani; Shyam S Kothari; Anita Saxena; Vinay K Bahl; Randeep Guleria
Journal:  BMJ Open       Date:  2013-03-11       Impact factor: 2.692

6.  Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease.

Authors:  R Condliffe; P Clift; K Dimopoulos; R M R Tulloh
Journal:  Pulm Circ       Date:  2018-07-23       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.